Olema Pharmaceuticals, Inc. (OLMA) saw its stock price plummet 5.01% during intraday trading on Wednesday.
The decline followed news that Guggenheim lowered its price target on Olema Oncology to $35 from $38, while maintaining a Buy rating on the shares. Analyst price target reductions are often viewed negatively by the market and can trigger selling pressure.